Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prexton

- PMLiVE

Lundbeck and Otsuka take Alzheimer’s drug into phase III

Lu AE58054 affects levels of serotonin in the brain

- PMLiVE

Lundbeck buoyed by Brintellix approval in US

FDA gives green light for to Cipralex/Lexapro successor in depression

- PMLiVE

Lundbeck presses on with cost-saving programme

Will cut up to 200 business services jobs in Europe

Biogen Idec building

Biogen Idec to develop Parkinson’s drugs with Amicus

Companies will develop treatments to target genetic mutation

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Lundbeck losses deepen on EU fine

Pay-for-delay penalty contributes to operating loss of 506m Danish krone

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

Lundbeck to cut 50 jobs in Europe

Part of restructuring operations to cope with patent loss for Cipralex/ Lexapro

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

- PMLiVE

Merck & Co drops Parkinson’s prospect preladenant

No better than placebo during phase III trial

- PMLiVE

Chasing the cure for Parkinson’s disease

Research for this common neurodegenerative disease has made remarkable progress over the last decade, but current therapies can only reduce its symptoms

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links